Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma
• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes.
Gespeichert in:
| Autor*in: |
Kamiya-Matsuoka, Carlos [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR - Song, Chun-hui ELSEVIER, 2023, Burlington, Mass |
|---|---|
| Übergeordnetes Werk: |
volume:74 ; year:2020 ; pages:36-40 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jocn.2020.01.066 |
|---|
| Katalog-ID: |
ELV049964445 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV049964445 | ||
| 003 | DE-627 | ||
| 005 | 20230624160854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jocn.2020.01.066 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica |
| 035 | |a (DE-627)ELV049964445 | ||
| 035 | |a (ELSEVIER)S0967-5868(19)32172-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.00 |2 bkl | ||
| 100 | 1 | |a Kamiya-Matsuoka, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| 264 | 1 | |c 2020 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. | ||
| 650 | 7 | |a Adverse events |2 Elsevier | |
| 650 | 7 | |a Physician’s decision |2 Elsevier | |
| 650 | 7 | |a Recurrent glioblastoma |2 Elsevier | |
| 650 | 7 | |a Survival |2 Elsevier | |
| 650 | 7 | |a Bevacizumab |2 Elsevier | |
| 700 | 1 | |a Hamza, Mohamed A. |4 oth | |
| 700 | 1 | |a de Groot, John F. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Song, Chun-hui ELSEVIER |t New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |d 2023 |g Burlington, Mass |w (DE-627)ELV009125612 |
| 773 | 1 | 8 | |g volume:74 |g year:2020 |g pages:36-40 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jocn.2020.01.066 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.00 |j Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 74 |j 2020 |h 36-40 |g 5 | ||
| author_variant |
c k m ckm |
|---|---|
| matchkey_str |
kamiyamatsuokacarloshamzamohamedadegroot:2020----:matfdeseetobvczmbnuvvlucmsfains |
| hierarchy_sort_str |
2020 |
| bklnumber |
35.00 |
| publishDate |
2020 |
| allfields |
10.1016/j.jocn.2020.01.066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica (DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 DE-627 ger DE-627 rakwb eng 540 VZ 35.00 bkl Kamiya-Matsuoka, Carlos verfasserin aut Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma 2020 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier Hamza, Mohamed A. oth de Groot, John F. oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:74 year:2020 pages:36-40 extent:5 https://doi.org/10.1016/j.jocn.2020.01.066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 74 2020 36-40 5 |
| spelling |
10.1016/j.jocn.2020.01.066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica (DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 DE-627 ger DE-627 rakwb eng 540 VZ 35.00 bkl Kamiya-Matsuoka, Carlos verfasserin aut Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma 2020 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier Hamza, Mohamed A. oth de Groot, John F. oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:74 year:2020 pages:36-40 extent:5 https://doi.org/10.1016/j.jocn.2020.01.066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 74 2020 36-40 5 |
| allfields_unstemmed |
10.1016/j.jocn.2020.01.066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica (DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 DE-627 ger DE-627 rakwb eng 540 VZ 35.00 bkl Kamiya-Matsuoka, Carlos verfasserin aut Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma 2020 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier Hamza, Mohamed A. oth de Groot, John F. oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:74 year:2020 pages:36-40 extent:5 https://doi.org/10.1016/j.jocn.2020.01.066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 74 2020 36-40 5 |
| allfieldsGer |
10.1016/j.jocn.2020.01.066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica (DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 DE-627 ger DE-627 rakwb eng 540 VZ 35.00 bkl Kamiya-Matsuoka, Carlos verfasserin aut Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma 2020 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier Hamza, Mohamed A. oth de Groot, John F. oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:74 year:2020 pages:36-40 extent:5 https://doi.org/10.1016/j.jocn.2020.01.066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 74 2020 36-40 5 |
| allfieldsSound |
10.1016/j.jocn.2020.01.066 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica (DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 DE-627 ger DE-627 rakwb eng 540 VZ 35.00 bkl Kamiya-Matsuoka, Carlos verfasserin aut Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma 2020 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier Hamza, Mohamed A. oth de Groot, John F. oth Enthalten in Harcourt Song, Chun-hui ELSEVIER New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR 2023 Burlington, Mass (DE-627)ELV009125612 volume:74 year:2020 pages:36-40 extent:5 https://doi.org/10.1016/j.jocn.2020.01.066 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.00 Chemie: Allgemeines VZ AR 74 2020 36-40 5 |
| language |
English |
| source |
Enthalten in New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR Burlington, Mass volume:74 year:2020 pages:36-40 extent:5 |
| sourceStr |
Enthalten in New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR Burlington, Mass volume:74 year:2020 pages:36-40 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Adverse events Physician’s decision Recurrent glioblastoma Survival Bevacizumab |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| authorswithroles_txt_mv |
Kamiya-Matsuoka, Carlos @@aut@@ Hamza, Mohamed A. @@oth@@ de Groot, John F. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009125612 |
| dewey-sort |
3540 |
| id |
ELV049964445 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049964445</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624160854.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jocn.2020.01.066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049964445</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0967-5868(19)32172-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kamiya-Matsuoka, Carlos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse events</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Physician’s decision</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Recurrent glioblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bevacizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamza, Mohamed A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Groot, John F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Song, Chun-hui ELSEVIER</subfield><subfield code="t">New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR</subfield><subfield code="d">2023</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV009125612</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:36-40</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jocn.2020.01.066</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2020</subfield><subfield code="h">36-40</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| author |
Kamiya-Matsuoka, Carlos |
| spellingShingle |
Kamiya-Matsuoka, Carlos ddc 540 bkl 35.00 Elsevier Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| authorStr |
Kamiya-Matsuoka, Carlos |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009125612 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 35.00 bkl Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab Elsevier |
| topic |
ddc 540 bkl 35.00 Elsevier Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab |
| topic_unstemmed |
ddc 540 bkl 35.00 Elsevier Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab |
| topic_browse |
ddc 540 bkl 35.00 Elsevier Adverse events Elsevier Physician’s decision Elsevier Recurrent glioblastoma Elsevier Survival Elsevier Bevacizumab |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m a h ma mah g j f d gjf gjfd |
| hierarchy_parent_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| hierarchy_parent_id |
ELV009125612 |
| dewey-tens |
540 - Chemistry |
| hierarchy_top_title |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009125612 |
| title |
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| ctrlnum |
(DE-627)ELV049964445 (ELSEVIER)S0967-5868(19)32172-1 |
| title_full |
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| author_sort |
Kamiya-Matsuoka, Carlos |
| journal |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| journalStr |
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
36 |
| author_browse |
Kamiya-Matsuoka, Carlos |
| container_volume |
74 |
| physical |
5 |
| class |
540 VZ 35.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kamiya-Matsuoka, Carlos |
| doi_str_mv |
10.1016/j.jocn.2020.01.066 |
| dewey-full |
540 |
| title_sort |
impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| title_auth |
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| abstract |
• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. |
| abstractGer |
• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. |
| abstract_unstemmed |
• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma |
| url |
https://doi.org/10.1016/j.jocn.2020.01.066 |
| remote_bool |
true |
| author2 |
Hamza, Mohamed A. de Groot, John F. |
| author2Str |
Hamza, Mohamed A. de Groot, John F. |
| ppnlink |
ELV009125612 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.jocn.2020.01.066 |
| up_date |
2024-07-06T23:01:36.779Z |
| _version_ |
1803872524597985280 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049964445</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624160854.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jocn.2020.01.066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001169.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049964445</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0967-5868(19)32172-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kamiya-Matsuoka, Carlos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Bevacizumab is widely used for treatment of recurrent glioblastoma (rGB). • Patients who discontinued bevacizumab because of AEs progressed earlier. • Development of AEs to bevacizumab is associated with unfavorable survival outcomes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse events</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Physician’s decision</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Recurrent glioblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bevacizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamza, Mohamed A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Groot, John F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Song, Chun-hui ELSEVIER</subfield><subfield code="t">New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR</subfield><subfield code="d">2023</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV009125612</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:36-40</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jocn.2020.01.066</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2020</subfield><subfield code="h">36-40</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.399748 |